Georgia Deliyannis, Nicholas A Gherardin, Chinn Yi Wong, Samantha L Grimley, James P Cooney, Samuel J Redmond, Paula Ellenberg, Kathryn C Davidson, Francesca L Mordant, Tim Smith, Marianne Gillard, Ester Lopez, Julie McAuley, Chee Wah Tan, Jing J Wang, Weiguang Zeng, Mason Littlejohn, Runhong Zhou, Jasper Fuk-Woo Chan, Zhi-Wei Chen, Airn E Hartwig, Richard Bowen, Jason M Mackenzie, Elizabeth Vincan, Joseph Torresi, Katherine Kedzierska, Colin W Pouton, Tom P Gordon, Lin-Fa Wang, Stephen J Kent, Adam K Wheatley, Sharon R Lewin, Kanta Subbarao, Amy W Chung, Marc Pellegrini, Trent Munro, Terry Nolan, Steven Rockman, David C Jackson, Damian F J Purcell, Dale I Godfrey
BACKGROUND: The SARS-CoV-2 global pandemic has fuelled the generation of vaccines at an unprecedented pace and scale. However, many challenges remain, including: the emergence of vaccine-resistant mutant viruses, vaccine stability during storage and transport, waning vaccine-induced immunity, and concerns about infrequent adverse events associated with existing vaccines. METHODS: We report on a protein subunit vaccine comprising the receptor-binding domain (RBD) of the ancestral SARS-CoV-2 spike protein, dimerised with an immunoglobulin IgG1 Fc domain...
May 4, 2023: EBioMedicine